These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 20547866)

  • 1. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
    Krieg C; Létourneau S; Pantaleo G; Boyman O
    Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11906-11. PubMed ID: 20547866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
    Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
    Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy.
    Su EW; Moore CJ; Suriano S; Johnson CB; Songalia N; Patterson A; Neitzke DJ; Andrijauskaite K; Garrett-Mayer E; Mehrotra S; Paulos CM; Doedens AL; Goldrath AW; Li Z; Cole DJ; Rubinstein MP
    Sci Transl Med; 2015 Oct; 7(311):311ra170. PubMed ID: 26511507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
    Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
    Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2.
    Courtney LP; Phelps JL; Karavodin LM
    Immunopharmacology; 1994; 28(3):223-32. PubMed ID: 7852053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2/IL-2 antibody immune complex regulates HSV-induced inflammation through induction of IL-2 receptor alpha, beta, and gamma in a mouse model.
    Choi JY; Choi B; Shim JA; Lee ES; Kim DY; Bang D; Sohn S
    Immunobiology; 2015 Dec; 220(12):1381-92. PubMed ID: 26213097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
    Kamimura D; Sawa Y; Sato M; Agung E; Hirano T; Murakami M
    J Immunol; 2006 Jul; 177(1):306-14. PubMed ID: 16785526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
    Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
    Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of metastases with lymphocytes treated with exogenous RNA in mice bearing B16 melanoma.
    Watanabe MA; Almeida DO; Serrano SV; Sales VS; Soares FA; de Lucca FL
    Cell Mol Biol (Noisy-le-grand); 1997 May; 43(3):393-8. PubMed ID: 9193794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25.
    Létourneau S; van Leeuwen EM; Krieg C; Martin C; Pantaleo G; Sprent J; Surh CD; Boyman O
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2171-6. PubMed ID: 20133862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy.
    Katz A; Shulman LM; Porgador A; Revel M; Feldman M; Eisenbach L
    J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):98-109. PubMed ID: 8318501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
    Yang SC; Fry KD; Grimm EA; Roth JA
    J Immunother (1991); 1991 Oct; 10(5):326-35. PubMed ID: 1790140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
    Becker JC; Pancook JD; Gillies SD; Furukawa K; Reisfeld RA
    J Exp Med; 1996 May; 183(5):2361-6. PubMed ID: 8642346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.
    Lopes JE; Sun L; Flick HL; Murphy EA; Losey HC
    J Pharmacol Exp Ther; 2021 Nov; 379(2):203-210. PubMed ID: 34362793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.